text
"[""\nXII. 상세표\n1. 연결대상 종속회사 현황(상세)\n☞ 본문 위치로 이동\n(단위 : 천원)\n상호\n설립일\n주소\n주요사업\n최근사업연도말자산총액\n지배관계 근거\n주요종속회사 여부\n셀트리온제약\n2000.11.17\n충청북도 청주시 청원군 오창읍 2산단로 82\n완제의약품 제조 및 판매\n548,074,598\n지분 50%초과보유\n해당(자산총액750억원 이상)\nCelltrion Pharma USA(*1)\n2008.01.25\n10535 wilshire Blvd. #D-04 Los Angeles,CA 90024\n서비스사업 관련업\n33,318\n지분 50%초과보유\n해당없음\n셀트리온유럽\n2009.07.21\n4th Floor, 15 Basinghall Street, London,EC2V 5BR, UK\nEU 지역내 바이오시밀러 임상시험 수행\n2\n지분 50%초과보유\n해당없음\nCelltrion Global Safety Data Center\n2018.05.23\nUnit 2201, 22th floor, One Global Place, 5th Avenue Corner 25th Street,Bonifacio Global City, Taguig, 1634 Metro Manila, Philippines\n글로벌 의약품 안전성 데이터 관리\n1,896,634\n지분 50%초과보유\n해당없음\nCelltrion USA\n2018.07.24\n1209 Orange Street, City of Wilmington, County of New Castle, 19801\n케미컬의약품 판매유통망 구축\n12,816,032\n지분 50%초과보유\n해당없음\nCelltrion Biopharma\n2019.02.13\n1st Floor, 6 Lapp's Quay, Cork, T12 VY7W, Ireland\n바이오시밀러 임상시험\n-\n지분 50%초과보유\n해당없음\nCelltrion Group Hongkong ltd\n2019.03.15\nUnit 1101, Enterprise Square, Tower 1,9 Sheung Yuet Road, Kowloon Bay, Kowloon, Hongkong\n바이오의약품 중국사업\n35,652,936\n지분 50%초과보유\n해당없음\nVcell Healthcare(*2)\n2018.11.01\nUnit 1101, Enterprise Square, Tower 1, 9 Sheung Yuet Road, Kowloon Bay, Kowloon, Hongkong\n바이오의약품 중국사업\n8,128,473\n지분 50%초과보유\n해당없음\nShanghai Vcell Biotech(*2)\n2019.04.09\n上海市浦東新區南彙新城鎭芦潮港路1969號219室\n바이오의약품 임상시험 등 연구개발\n1,567,901\n지분 50%초과보유\n해당없음\nCelltrion Asia Pacific PTE\n2020.08.12\n6 Eu Tong Sen Street #11-10C, The Central Singapore, 059817\n케미컬의약품 판매 및 연구개발\n325,408,677\n지분 50%초과보유\n해당(자산총액750억원 이상)\n(*1) 셀트리온제약이 100%의 지분을 보유하고 있었으며,\xa0당기 중 청산되어 종속기업에서\xa0제외되었습니다.(*2)\xa0Celltrion Group Hongkong이 100%의 지분을 보유하고 있습니다.\n2. 계열회사 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2021년 09월 30일\n)\n(단위 : 사)\n상장여부\n회사수\n기업명\n법인등록번호\n상장\n3\n(주)셀트리온\n133-81-23603\n(주)셀트리온헬스케어\n132-81-53473\n(주)셀트리온제약\n214-86-71641\n비상장\n5\n(주)셀트리온홀딩스\n131-86-24858\n(주)셀트리온헬스케어홀딩스\n480-86-01873\n(주)셀트리온엔터테인먼트\n107-87-63802\n(주)셀트리온스킨큐어\n105-86-13560\n(주)티에스이엔씨\n122-81-87650\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2021년 09월 30일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nA&G Pharmaceutical, Inc\n비상장\n2006.07.14\n단순투자\n2,676,548\n987,889\n16.51\n116,349\n-\n-\n-\n987,889\n16.51\n116,349\n2,912,601\n1,062,859\n셀트리온 유럽\n비상장\n2009.07.21\n경영참여\n2\n1\n100.00\n2\n-\n-\n-\n1\n100\n2\n2\n-\n바이오톡스텍\n상장\n2009.07.28\n단순투자\n2,025,000\n1,631,134\n11.15\n24,793,236\n-\n-\n-9,786,804\n1,631,134\n11.12\n15,006,432\n63,705,372\n2,016,035\n보스톤 인큐베이션투자조합\n비상장\n2009.11.27\n일반투자\n2,500,000\n11\n25.00\n83,007\n-\n-\n-\n11\n25\n83,007\n336,194\n-2,342\n제이티비씨\n비상장\n2017.09.20\n단순투자\n500,000\n100,000\n0.09\n33,940\n-\n-\n34,046\n100,000\n0.09\n67,986\n401,083,935\n-25,497,001\n프리미어 글로벌 이노베이션 1호\n비상장\n2017.06.15\n단순투자\n250,000\n3,445\n6.67\n3,444,767\n-602\n-601,909\n-\n2,843\n6.67\n2,842,858\n99,189,160\n24,256,551\n프리미어 글로벌 이노베이션 2호\n비상장\n2020.11.05\n단순투자\n250,000\n250\n5.56\n250,000\n1,750\n1,750,000\n-\n2,000\n5.56\n2,000,000\n4,500,138\n-188,067\n매일방송\n비상장\n2011.03.17\n단순투자\n1,000,000\n250,981\n0.48\n1,475,167\n-\n-\n-\n250,981\n0.48\n1,475,167\n393,311,270\n1,890,589\n뉴스1\n비상장\n2011.06.09\n단순투자\n500,000\n60,000\n5.00\n300,000\n-60,000\n-300,000\n-\n0\n0\n0\n22,282,973\n2,335,332\n셀트리온제약\n상장\n2013.04.23\n경영참여\n50,057,259\n19,682,190\n54.96\n255,342,176\n393,643\n-\n-\n20,075,833\n54.93\n255,342,176\n548,074,598\n20,936,032\n2014 성장사다리-IMM 벤처펀드\n비상장\n2014.08.11\n일반투자\n2,000,000\n2,500\n20.00\n1,683,844\n-336\n-336,000\n-\n2,164\n20\n1,347,844\n9,083,445\n-1,724,638\n미래에셋 셀트리온신성장 투자조합 1호\n비상장\n2017.03.31\n일반투자\n6,250,000\n425\n50.00\n42,500,000\n15\n1,500,000\n-\n440\n50\n44,000,000\n92,202,238\n1,646,447\nCelltrion Global Safety Data Center\n비상장\n2018.05.23\n경영참여\n1,106,930\n580,563\n99.99\n1,204,581\n-\n-\n-\n580,563\n99.99\n1,204,581\n1,896,634\n200,712\nCelltrion USA, Inc.\n비상장\n2018.07.24\n경영참여\n38,973\n3,050\n100.00\n6,951,601\n-\n-\n-\n3,050\n100\n6,951,601\n12,816,032\n-8,632,880\nCelltrion Group Hongkong ltd\n비상장\n2019.04.01\n경영참여\n5,680,500\n7,023,270\n70.00\n8,086,365\n-\n-\n-\n7,023,270\n70\n8,086,365\n29,554,539\n-547,241\n셀트리온충북대 바이오메딕스\n비상장\n2018.07.18\n경영참여\n100,000\n20,000\n50.00\n100,000\n-\n-\n-\n20,000\n50\n100,000\n152,990\n-15,974\nIksuda Therapeutics Limited\n비상장\n2021.06.01\n경영참여\n9,031,863\n-\n-\n-\n717,112\n9,031,863\n-\n717,112\n17.79\n9,031,863\n3,672,337\n-5,870,059\nCelltrion Asia Pacific PTE\n비상장\n2020.11.23\n경영참여\n315,987,120\n283,600,000\n100.00\n315,987,120\n-\n-\n-\n283,600,000\n100\n315,987,120\n325,408,677\n-3,294,286\n합 계\n313,945,709\n-\n662,352,155\n1,051,582\n11,043,954\n-9,752,758\n314,997,291\n-\n663,643,351\n2,010,183,135\n14,442,128\n""]"
